Azitra, Inc.

-Financing marks launch of Azitra new innovative protein and peptide research programs for the cosmetic and cosmeceutical markets -Leverages untapped potential of Azitra's genetic engineering platform to accelerate time to commercialization

Highlights from our announcement yesterday: -Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants #biotech #dermatology #cosmeceutical $AZTR

@azitrainc Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million ir.azitrainc.com/news-releases/…

How is @azitrainc's approach to precision dermatology differentiated? Designed to penetrate/delivers to skin; disease modifying; safe; low cost; and ease of use. Learn more here azitrainc.com/technology/

What's Ichthyosis vulgaris? Characterized by dry, rough, & scaly skin, caused by loss-of-function mutations in the filaggrin gene; a common autosomal dominant disease. No FDA-approved options. Learn about #IchthyosisVulgaris & the rest of our pipeline: azitrainc.com/pipeline/

Last week we announced the addition of MD Anderson Cancer Center as clinical site for our Phase 1/2 trial of ATR-04 targeting EGFRi-Associated Skin Rash - learn more about ATR-04 here $AZTR #CancerRash #ATR-04" target="_blank" rel="nofollow noopener">azitrainc.com/pipeline/#ATR-…

Thanks for the interest today - here's our COO & co-founder Travis Whitfill speaking to the crowd at BIO Investment & Growth Summit #Biotech #innovation #BIO #precisionmedicine #precisionderm $AZTR

@azitrainc to Present at BIO Investment & Growth Summit #Biotech #innovation #BIO $AZTR ir.azitrainc.com/news-releases/…

More from today's announcement from @azitrainc's CEO Francisco Salva - Announcing the addition of MD Anderson Cancer Center as a #clinical site for our Phase 1/2 trial of ATR-04 targeting #EGFRiAssociated #SkinRash #PrecisionDerm #biotech #CancerRash $AZTR ir.azitrainc.com/news-releases/…

@azitrainc Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash #ClinicalTrial #PrecisionMedicine #PrecisionDerm #biotech #CancerRash $AZTR ir.azitrainc.com/news-releases/…

More from the recent #ScripAsks with @azitrainc COO Travis Whitfill discussing #ClinicalTrials & Regulatory Efficiency #RareDisease #biotech #innovation #precisionmedicine $AZTR

From @Citeline's #ScripAsks - @azitrainc COO Travis Whitfill was included in discussion on #ClinicalTrial & Regulatory Efficiency $AZTR Read the full article here: insights.citeline.com/scrip/scrip-as…

At @azitrainc, we're combining 3 foundational platforms for precision dermatology: -Proprietary, robust library of ~1,500 microbial strains -#ArtificialIntelligence / #MachineLearning Discovery -Microbial #GeneticEngineering Platform #PrecisionDerm $AZTR azitrainc.com/technology/

Engineered microbes for microbial #drugdelivery - @azitrainc engineers commensal skin bacteria to deliver critical missing natural proteins and disease-modifying proteins directly to the target and through the stratum corneum of the skin. #engineered-microbes" target="_blank" rel="nofollow noopener">azitrainc.com/technology/#en… #Biotech $AZTR

What's the mechanism behind our candidate for #IchthyosisVulgaris? ATR-01 is designed to deliver missing filaggrin #protein to result in restoration of the skin barrier & skin hydration #biotech #skindisease #raredisease For more see our #Pipeline page azitrainc.com/pipeline/

Be sure to check out the #ScipAsks series @Citeline. What Does 2026 Hold For Biopharma? Our COO Travis Whitfill was quoted in Part 2 on #RareDisease $AZTR Read the full article here insights.citeline.com/scrip/scrip-as… @azitrainc

From @Citeline's #ScripAsks - @azitrainc COO Travis Whitfill on #RareDisease $AZTR Read the full article here: insights.citeline.com/scrip/scrip-as…

A great read - Co-Founder & COO Travis Whitfill was featured in this week's Scrip Asks... What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped #RareDisease $AZTR insights.citeline.com/scrip/scrip-as…

Here's Co-Founder & COO Travis Whitfill @twhitfill presenting at Biotech Showcase today. #Biotech #Raredisease #precisionderm $AZTR

In case you missed it - @azitrainc presenting at Biotech Showcase in San Francisco Jan 13 #JPM26 #precisionderm #raredisease ir.azitrainc.com/news-releases/…

@azitrainc to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference #biotech #JPM26 #precisionderm #raredisease ir.azitrainc.com/news-releases/…